All In Biotech

Drug Trial Radar · NCT02138825

Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)

A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).

Last checked: Nov 20, 2026Latest source record: Dec 4, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 147 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

147

Actual

Start

Jun 4, 2014

Primary completion

May 5, 2016

Study completion Sep 14, 2016

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
May 15, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of 26-weeks of treatment with riociguat vs. placebo in patients with symptomatic PH (pulmonary hypertension) associated with IIP (idiopathic interstitial pneumonias).

Conditions

  • Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary

Interventions

  • Riociguat (Adempas, BAY63-2521)Drug

    Active drug 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID/day as per individual dose titration. The starting dose will be 0.5 mg TID, and the dose will be adjusted every two weeks for ten weeks in 0.5 mg increments up to a maximum dose of 2.5 mg TID based on patient's systolic blood pressure and well-being.

  • PlaceboDrug

    Inactive dosed at 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID/day as per individual dose titration for 26 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change in 6 Minute Walking Distance (6MWD) From Baseline to Week 26Time frame: Baseline to 26 weeks

Locations

93 sites in 21 countries. Site status is shown where the registry gives one.

  • University of California, Los Angeles

    Los Angeles, California

  • Site not named

    San Francisco, California

  • Site not named

    Aurora, Colorado

  • Site not named

    Miami, Florida

  • Site not named

    Orlando, Florida

  • Via Christi Clinic

    Wichita, Kansas

  • Site not named

    Louisville, Kentucky

  • Columbia University Medical Center

    New York, New York

  • Site not named

    Durham, North Carolina

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Cleveland, Ohio

  • Site not named

    Columbus, Ohio

  • Site not named

    Portland, Oregon

  • Site not named

    Pittsburgh, Pennsylvania

  • Site not named

    Nashville, Tennessee

  • Site not named

    Dallas, Texas

  • Site not named

    Falls Church, Virginia

  • Site not named

    Mar del Plata, Buenos Aires, Argentina

  • Site not named

    Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

  • Site not named

    Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

  • Site not named

    Godoy Cruz, Mendoza Province, Argentina

  • Site not named

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Site not named

    Camperdown, New South Wales, Australia

  • Site not named

    Darlinghurst, New South Wales, Australia

  • Site not named

    Sydney, New South Wales, Australia

  • Site not named

    Chermside, Queensland, Australia

  • Site not named

    Adelaide, South Australia, Australia

  • Site not named

    Prahran, Victoria, Australia

  • Site not named

    Murdoch, Western Australia, Australia

  • Site not named

    Leuven, Belgium

  • Site not named

    Québec, Canada

  • Site not named

    Vancouver, British Columbia, Canada

  • Site not named

    Ottawa, Ontario, Canada

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    Bogotá, Colombia

  • Site not named

    Bogotá, Bogota D.C., Colombia

  • Site not named

    Floridablanca-Bucaramanga, Santander Department, Colombia

  • Site not named

    Cali, Valle del Cauca Department, Colombia

  • Site not named

    Aarhus N, Denmark

  • Site not named

    Bron, France

Showing 40 of 93 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.